超越转位子:TIGD1作为泛癌生物标志物和免疫调节器
Merve Gulsen Bal Albayrak1, Tuğcan Korak1, Gurler Akpinar1
1Department of Medical Biology, Faculty of Medicine, Kocaeli University, Kabaoglu District, Baki Komsuoglu Blvd. No:21, Umuttepe, 41001 Kocaeli, Turkey.
Genes
|June 26, 2025
概括
触发式可转移元素衍生1 (TIGD1) 是一种在许多癌症,特别是结肠腺癌中升级的瘤基因. 高TIGD1表达与预后不佳和治疗耐药性相关,表明其作为生物标志物和治疗点的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 触发式可转移元件衍生1 (TIGD1) 是一种新发现的癌基因,其功能尚未完全理解.
- 有证据表明,TIGD1参与了与癌症发展相关的各种细胞过程.
- 需要进行全面的泛癌分析,以澄清TIGD1在瘤学中的作用.
研究的目的:
- 进行TIGD1表达,诊断价值和预后意义的泛癌分析.
- 研究TIGD1与瘤免疫微环境的关联以及对免疫治疗的反应.
- 探索TIGD1在抗药性中的作用及其作为治疗点的潜力.
主要方法:
- 利用了来自癌症基因组图谱 (TCGA) 和基因型-组织表达 (GTEx) 项目的转录和临床数据.
- 进行表达特征分析,生存分析,免疫相关性研究和基因组丰富分析.
- 进行单细胞测序和药物敏感性评估,以评估TIGD1的功能影响.
主要成果:
- 在多种癌症类型中,TIGD1显著上调,特别是在结肠腺癌中.
- 提升的TIGD1表达与更差的预后相关,并与对Zoledronate,Dasatinib和BLU-667的耐药性有关.
- 与瘤免疫微环境特征相关的TIGD1表达,包括免疫检查点基因,TMB和MSI,并与瘤性途径有关.
结论:
- 作为结肠癌,胃癌,肝癌和肺癌的诊断和预后生物标志物,TIGD1显示出希望.
- TIGD1对抗瘤免疫的调节和与治疗耐药性的关联凸显了其作为新目标的潜力.
- 对TIGD1的进一步研究可能会导致精确瘤学和免疫治疗策略的进步.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
03:18Non-LTR Retrotransposons
11.9K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.9K
01:27Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K